Physician profile
Samer Salka
NPI 1811956139
$9,581.24
in general payments reported to CMS, 2019-2025
40 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $1,290 · 2021: $1,399 · 2022: $1,331 · 2023: $1,441 · 2024: $2,505 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,594 · Travel and Lodging: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,593.90 |
| Travel and Lodging | $852.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,334.89 | 2019-2024 | Xarelto |
| Medtronic, INC. | $940.85 | 2024-2025 | Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $883.99 | 2020-2025 | Lifevest |
| Boston Scientific Corporation | $879.43 | 2019-2024 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor, Wolverine Coronary Cutting Balloon |
| Novartis Pharmaceuticals Corporation | $784.52 | 2019-2024 | |
| Pfizer INC. | $597.72 | 2019-2024 | |
| Amarin Pharma, INC. | $476.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $420.30 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $395.95 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $319.60 | 2020-2024 | Repatha |
| Heartflow, INC. | $316.98 | 2023-2024 | Ffrct |
| Novo Nordisk INC | $304.94 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $240.43 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.36 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $215.32 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $172.02 | 2023-2024 | Inpefa |
| Biosense Webster, INC. | $145.83 | 2025 | Carto 3 |
| Scpharmaceuticals INC. | $115.11 | 2023-2024 | |
| United Therapeutics Corporation | $91.62 | 2019-2024 | Tyvaso |
| Lundbeck LLC | $90.07 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $75.32 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $70.09 | 2021-2024 | Opsumit |
| Chiesi USA, INC. | $51.48 | 2019-2021 | |
| Preventice Services, LLC | $44.60 | 2019-2021 | |
| Edwards Lifesciences Corporation | $44.28 | 2019-2020 | |
| Tactile Systems Technology INC | $38.80 | 2019-2023 | Flexitouch Plus, Entre Plus |
| Abbott Laboratories | $33.41 | 2020-2023 | Cardiomems |
| Kiniksa Pharmaceuticals, LTD. | $33.39 | 2023 | Arcalyst |
| Astellas Pharma US INC | $33.01 | 2020-2023 | Lexiscan |
| Philips North America LLC | $31.02 | 2024 | (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $30.63 | 2024 | Arcalyst |
| Inari Medical, INC. | $23.56 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Esperion Therapeutics, INC. | $23.55 | 2020 | |
| Cordis US Corp. | $19.37 | 2024 | Mynxgrip |
| Bayer Healthcare Pharmaceuticals INC. | $17.39 | 2021 | |
| Lilly USA, LLC | $15.81 | 2024 | Mounjaro |
| Baxter Healthcare | $15.22 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $14.95 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.42 | 2024 | Onpattro |
| Zoll Circulation INC | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Salka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.